173 related articles for article (PubMed ID: 32891176)
21. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
[TBL] [Abstract][Full Text] [Related]
22. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
Babiker HM; Byron SA; Hendricks WPD; Elmquist WF; Gampa G; Vondrak J; Aldrich J; Cuyugan L; Adkins J; De Luca V; Tibes R; Borad MJ; Marceau K; Myers TJ; Paradiso LJ; Liang WS; Korn RL; Cridebring D; Von Hoff DD; Carpten JD; Craig DW; Trent JM; Gordon MS
Invest New Drugs; 2019 Aug; 37(4):636-645. PubMed ID: 30264293
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
24. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
[TBL] [Abstract][Full Text] [Related]
25. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Wilmott JS; Tawbi H; Engh JA; Amankulor NM; Shivalingam B; Banerjee H; Vergara IA; Lee H; Johansson PA; Ferguson PM; Saiag P; Robert C; Grob JJ; Butterfield LH; Scolyer RA; Kirkwood JM; Long GV; Davies MA
Clin Cancer Res; 2023 Feb; 29(3):521-531. PubMed ID: 36477181
[TBL] [Abstract][Full Text] [Related]
26. Current and emerging options for patients with melanoma brain metastases.
Kreidieh FY; Tawbi HA
Clin Adv Hematol Oncol; 2022 Oct; 20(10):619-627. PubMed ID: 36206074
[TBL] [Abstract][Full Text] [Related]
27. Clinical protein science in translational medicine targeting malignant melanoma.
Gil J; Betancourt LH; Pla I; Sanchez A; Appelqvist R; Miliotis T; Kuras M; Oskolas H; Kim Y; Horvath Z; Eriksson J; Berge E; Burestedt E; Jönsson G; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Murillo JR; Sugihara Y; Welinder C; Wieslander E; Lee B; Lindberg H; Pawłowski K; Kwon HJ; Doma V; Timar J; Karpati S; Szasz AM; Németh IB; Nishimura T; Corthals G; Rezeli M; Knudsen B; Malm J; Marko-Varga G
Cell Biol Toxicol; 2019 Aug; 35(4):293-332. PubMed ID: 30900145
[TBL] [Abstract][Full Text] [Related]
28. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.
Meier F; Will S; Ellwanger U; Schlagenhauff B; Schittek B; Rassner G; Garbe C
Br J Dermatol; 2002 Jul; 147(1):62-70. PubMed ID: 12100186
[TBL] [Abstract][Full Text] [Related]
29. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract][Full Text] [Related]
30. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
31. Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures.
Tanaka A; Ogawa M; Zhou Y; Namba K; Hendrickson RC; Miele MM; Li Z; Klimstra DS; Buckley PG; Gulcher J; Wang JY; Roehrl MHA
Cell Rep; 2024 Feb; 43(2):113810. PubMed ID: 38377004
[TBL] [Abstract][Full Text] [Related]
32. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR
Nat Commun; 2021 Nov; 12(1):6689. PubMed ID: 34795224
[TBL] [Abstract][Full Text] [Related]
33. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
Stejerean-Todoran I; Gimotty PA; Watters A; Brafford P; Krepler C; Godok T; Li H; Bonilla Del Rio Z; Zieseniss A; Katschinski DM; Sertel SM; Rizzoli SO; Garman B; Nathanson KL; Xu X; Chen Q; Oswald JH; Lotem M; Mills GB; Davies MA; Schön MP; Bogeski I; Herlyn M; Vultur A
Neuro Oncol; 2023 Apr; 25(4):674-686. PubMed ID: 36054930
[TBL] [Abstract][Full Text] [Related]
34. Melanoma brain metastases and vemurafenib: need for further investigation.
Rochet NM; Dronca RS; Kottschade LA; Chavan RN; Gorman B; Gilbertson JR; Markovic SN
Mayo Clin Proc; 2012 Oct; 87(10):976-81. PubMed ID: 23036672
[TBL] [Abstract][Full Text] [Related]
35. Current Treatment of Melanoma Brain Metastasis.
Rishi A; Yu HM
Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
[TBL] [Abstract][Full Text] [Related]
36. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.
Korabiowska M; König F; Verheggen R; Schlott T; Cordon-Cardo C; Romeike B; Brinck U
Anticancer Res; 2004; 24(2B):981-6. PubMed ID: 15161053
[TBL] [Abstract][Full Text] [Related]
37. Lack of distinct molecular profile of Primary Dermal Melanoma.
Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
[TBL] [Abstract][Full Text] [Related]
38. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.
Raskin L; Fullen DR; Giordano TJ; Thomas DG; Frohm ML; Cha KB; Ahn J; Mukherjee B; Johnson TM; Gruber SB
J Invest Dermatol; 2013 Nov; 133(11):2585-2592. PubMed ID: 23633021
[TBL] [Abstract][Full Text] [Related]
39. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
[TBL] [Abstract][Full Text] [Related]
40. The human melanoma proteome atlas-Defining the molecular pathology.
Betancourt LH; Gil J; Kim Y; Doma V; Çakır U; Sanchez A; Murillo JR; Kuras M; Parada IP; Sugihara Y; Appelqvist R; Wieslander E; Welinder C; Velasquez E; de Almeida NP; Woldmar N; Marko-Varga M; Pawłowski K; Eriksson J; Szeitz B; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Lindberg H; Oskolas H; Lee B; Berge E; Sjögren M; Eriksson C; Kim D; Kwon HJ; Knudsen B; Rezeli M; Hong R; Horvatovich P; Miliotis T; Nishimura T; Kato H; Steinfelder E; Oppermann M; Miller K; Florindi F; Zhou Q; Domont GB; Pizzatti L; Nogueira FCS; Horvath P; Szadai L; Tímár J; Kárpáti S; Szász AM; Malm J; Fenyö D; Ekedahl H; Németh IB; Marko-Varga G
Clin Transl Med; 2021 Jul; 11(7):e473. PubMed ID: 34323403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
